The Russian vaccine Sputnik V against Covid-19 “produced neutralizing protective titers against the new variants” of Sars-CoV-2 including “Alpha (B.1.1.7), Beta (B.1.351), Gamma P.1 ( first identified in Brazil), Delta (B.1.617.2) and B.1.617.3 (found in India for the first time) and Moscow endemic variants B.1.1.141 and B.1.1.317 “. The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (Rdif) announced in a note. The research behind these findings was published in the journal ‘Vaccines’. “To date Sputnik V has been registered in 67 countries around the world with a total population of over 3.5 billion people”, the Gamaleya center pointed out.
Says Alexander Gintsburg, director of Gamaleya: “Our studies have shown strong results of Sputnik V against the new variants of Sars-CoV-2”. Today Sputnik V “is one of the most effective vaccines against the already known and more recent variants of the coronavirus, thanks to its unique approach that involves the use of two different adenoviral vectors as a mechanism of action”.
The methodology used by Gamaleya for the study is based “on the evaluation of the neutralization activity of the virus (Vna) that the live virus uses and which provides the most reliable data and is the gold standard”, the note states.